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ABSTRACT 
A possible role for adenylate cyclase and guanine nucleotide¬ 
binding proteins (G-proteins) in contributing to the chronic actions of 
lithium on brain function was investigated in rat cerebral cortex. 
Northern blotting and Western blotting techniques were utilized to 
measure lithium induced changes in mRNA and protein levels of 
specific adenylate cyclase and G-protein subtypes. It was found that 
chronic treatment of rats with lithium (with therapeutically relevant 
serum levels of approximately 1 mM) increased levels of mRNA and 
protein for the calmodulin-sensitive (type 1) and calmodulin- 
insensitive (type 2) forms of adenylate cyclase and decreased levels of 
mRNA and protein for the inhibitory G-protein subunits Giai and Gia2- 
Chronic lithium did not alter levels of other G-protein subunits, 
including G0a> Gsa, and Gp. Lithium regulation of adenylate cyclase and 
Gia was not seen in response to short-term lithium treatment (with 
final serum levels of approximately 1 mM) or in response to chronic 
treatment at a lower dose of lithium (with serum levels of 
approximately 0.5 mM). The results suggest that up-regulation of 
adenylate cyclase and down-regulation of Gia could represent part of 
the molecular mechanism by which lithium alters brain function and 
exerts its clinical actions in the treatment of affective disorders. 
. 
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INTRODUCTION 
Lithium is the drug of choice for manic-depressive illness. 
In contrast to most psychotherapeutic agents which acutely 
affect neurotransmitter receptor activation, lithium appears to 
act initially upon post-receptor components of signal 
transduction. However, these acute effects do not correspond 
with the 2-4 week time course required for lithium's clinical 
efficacy. We have therefore sought to study the neuronal 
adaptations which occur in response to chronic lithium therapy 
in an effort to uncover the critical molecular changes which 
underlie lithium's therapeutic effect. Before considering the 
results of our chronic lithium studies, it will be useful to review 
the cyclic AMP (cAMP) and phophatidylinositol-bis-phosphate 
(PIP2) second messenger pathways and the acute actions of 
lithium on these signal transduction systems. 
Transmembrane signalling -- generation of cAMP as a second 
messenger 
Second messenger systems serve the important function 
of transforming an extracellular signal of a neurotransmitter 
(or hormone) into an intracellular signal, prompting an 
intracellular response. The cAMP system is "turned on" when 
a stimulatory agonist binds its receptor thereby inducing a 
configurational change. The agonist-receptor complex then 
interacts with the stimulatory G-protein, Gs, which is a trimer 
composed of Gsa, Gp, and Gy subunits. Upon interaction with the 
agonist receptor complex, GSa increases its affinity for GTP, and 
dissociates from the trimer. In the activated GTP-bound state 
GSa interacts with adenylate cyclase to stimulate the conversion 
of ATP to cAMP (Fig 1A). The water soluble second messenger, 
cAMP, binds to the regulatory subunits of cAMP-dependent 
protein kinase (PKA), composed of 2 regulatory and 2 catalytic 
subunits. Upon binding 4 molecules of cAMP (2 per regulatory 
subunit), the 2 catalytic subunits are released thus generating 
active catalytic subunits (Fig. IB). The free catalytic subunits 
■ 
phosphorylate substrate proteins, including ion channels, 
nuclear proteins, and other protein kinases, which regulate a 
wide range of cell functions (1). 
A. 
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Figure 1. The cAMP signal transduction pathway. A. The stimulatory 
hormone (neurotransmitter) binds its receptor, activates Gsa which 
stimulates adenylate cyclase to produce cAMP. B. The second messenger, 
cAMP, binds the regulatory subunits of PKA to liberate 2 active catalytic 
subunits. Figure adapted from Darnell, J., et. al. (2). 
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There are greater levels of complexity of cell regulation 
which extend beyond the scope of this discussion. However, it 
is important to note that cAMP levels are regulated by the 
activity of two opposing enzymatic processes — the conversion 
of ATP to cAMP by adenylate cyclase versus the degradation of 
cAMP to AMP by phosphodiesterase (1). There are also 
counter-regulatory mechanisms at the level of protein 
phosphorylation -- the phosphorylation of substrate proteins 
by protein kinases versus dephosphorylation by protein 
phosphatases (3). In sum, at each level there are homeostatic 
mechanisms to reverse transient changes in cell stimulation. 
Inhibitory agonists act through similar mechanisms as 
stimulatory agonists. However the exact mechanism of Gi 
inhibition of adenylate cyclase has not been clearly established. 
Inhibitory agonists bind inhibitory receptors and the agonist- 
receptor complex interacts with Gi inducing Gia binding of GTP 
and dissociation of the a-p-y trimer. It is unclear whether Gja 
directly inhibits adenylate cyclase or whether the liberation of 
free GpY dimers sequesters active GSaJ this would indirectly 
inhibit adenylate cyclase by suppressing its activation from 
Gsa. Through either direct or indirect means, stimulation of Gi 
decreases adenylate cyclase activity, decreases cAMP 
production, and thereby allows the regulatory subunits of PKA 
to inhibit the catalytic subunit (1). 
Transmembrane signalling -- PIP? hydrolysis 
The receptor mediated stimulation of phosphoinositide 
hydrolysis has recently been elucidated as a second major 
pathway of transmembrane signalling. Phosphoinositides are 
phospholipid components of the cell membrane. PIP2 is a 
member of this phospholipid family and is the substrate for 
generation of second messengers in this system. Receptor 
stimulation appears to activate phospholipase C (PLC) via the 
recently identified Gq class of G-proteins (3a). PLC hydrolyzes 
PIP2 into two products, water soluble inositol triphosphate 
(IP3) and diacylglycerol (DG) (4). IP3 acts upon the intracellular 
■ 
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IP3 receptor to liberate internal calcium stores. The elevation of 
cytoplasmic calcium concentration activates a variety of 
processes through the calcium binding protein, calmodulin, 
including stimulation of calcium-calmodulin dependent protein 
kinases (4). The lipophilic DG remains associated with the 
membrane where it interacts with protein kinase C (PKC). 
Activation of PKC is dependent on both the availability of DG 
and free calcium (Fig. 2). Similar to PKA, this enzyme 
phosphorylates a variety of substrate proteins and thereby 
regulates cell function (4). 
Figure 2. The PIP2 hydrolysis signal transduction pathway. The 
stimulatory agonist binds its receptor and activates PLC which 
hydrolyzes PIP2 to form the second messengers DG and IP3. Both PKC 
and calcium-calmodulin dependent protein kinases are activated in this 
cascade of events. Figure adapted from Catt, K.J. (5). 
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The genetics of transmembrane signalling 
As both the cAMP and PIP2 hydrolysis second messenger 
systems are vital components of cell regulation, the constituent 
proteins of these systems have been the target of many gene 
cloning experiments. One of the great surprises from these 
efforts has been the multiplicity of distinct genes encoding 
distinct subtypes of many of these signal transducing proteins 
including, G-proteins, adenylate cyclase, regulatory and 
catalytic subunits of PKA, PLC, and PKC. One functional 
consequence of this heterogeneity is that different tissues may 
respond to extracellular stimuli with different signal 
transducing machinery, and thereby have heterogeneous 
responsiveness to identical stimuli. Previous hypotheses had 
focused on heterogeneity at the receptor level as the major 
source of differential stimulus-response coupling in different 
tissues. 
From second messengers to regulation of gene transcription 
One of the central questions in biology is how cells 
exercise differential regulation of gene transcription. This 
question was first addressed in prokaryotes and has recently 
been studied in great depth in eukaryotic cells. There are two 
main aspects to this subject -- (i) tissue specific gene 
transcription (ie. the mechanisms by which a tissue can express 
a unique set of genes) and (ii) hormonal regulation of gene 
expression. We will focus on the latter topic with particular 
regard to cell surface signalling and the regulation of gene 
transcription by both the cAMP and PIP2 second messenger 
systems. 
Upon activation of the cAMP cascade, the catalytic 
subunit of PKA phosphorylates a myriad of cytoplasmic 
proteins and, in addition, translocates to the nucleus where it 
phosphorylates the cAMP regulatory element binding protein 
(CREB) at a single site, Ser-133 (6). Phosphorylation of CREB 
promotes mRNA transcription from genes which contain the 
cAMP regulatory element (CRE, 5'-TGACGTCA-3') in the 
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transcriptional promoter region (6). It is important to note that 
the presence of a CRE in the promoter region of a gene confers 
cAMP-inducibility to the gene. It is believed that when CREB 
binds the CRE it promotes formation of a transcriptional 
initiation complex at the TATA box -- at approximately -30 in a 
majority of eukaryotic genes (7). This process takes place in a 
stepwise fashion with TFIID being the first subunit of RNA 
polymerase II to bind in the TATA region, followed by IIA, IIB, 
and HE, to form a competent transcription complex. In fact, the 
enhancement of the TFIID-DNA interaction is believed to be a 
general mechanism whereby transcriptionally active proteins 
(via an a-helical acidic activating region) promote gene 
transcription (6). In sum, stimulation of the cAMP cascade 
directly regulates specific gene transcription of CRE-containing 
genes through PKA phosphorylation of CREB. 
The stimulation of PIP2 hydrolysis results in IP3- 
mediated rises in cytosolic Ca++ and PKC phosphorylation of 
substrate proteins. Activation of this second messenger 
pathway is believed to induce gene transcription by at least 
two mechanisms: (i) elevation of internal Ca++ leads to 
calmodulin-dependent phosphorylation of CREB (presumably 
via calmodulin-dependent protein kinase) and (ii) PKC activates 
transcription of the nuclear protein c-fos. In the case of PKC 
induction of c-fos it appears that PKC activates serum response 
factor (SRF), a transcriptionally active 67 kDa nuclear protein 
(6). Upon activation, SRF binds the serum response element 
(SRE) which is located at -310 in the c-fos gene, and thereby 
increases the rate of c-fos transcription (6). However, the 
mechanism through which PKC activates SRF is unknown. There 
is cross-talk between PKA-mediated and PKC-mediated events 
at the level of c-fos induction — the c-fos gene is induced by 
PKA, via CREB phosphorylation, which enhances transcription 
by binding the CRE located at -60 in the c-fos gene (6). In 
addition, Ca++ can also induce transcriptional activation of c-fos 
at the same CRE site, presumably by calmodulin-dependent 
protein kinase phosphorylation of CREB (6). In sum, cAMP, DAG, 
. 
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and Ca++ can independently activate c-fos transcription. In this 
manner the second messengers couple cellular stimulation to 
the regulation of c-fos transcription. We will now focus on c-fos 
as a regulator of gene transcription. 
Upon cell stimulation, c-fos mRNA levels rise within 30- 
45 minutes via the previously described second messenger 
systems. The c-fos protein is a 62 kDa nuclear protein that 
undergoes extreme post-translational modification (6). There 
are in fact several fos-related genes which have been cloned 
and sequenced. They all share regions of homology including 
the DNA binding domain and leucine-zipper region. This region 
is characterized by an interaction of leucine side chains, spaced 
7 amino acids apart, on adjacent a-helices (6). Through the 
leucine zipper fos binds another nuclear protein, jun, to form 
the transcriptionally active AP-1 complex. Genes which contain 
the AP-1 recognition site (5'-TGACTCA-3'), also known as the 
TPA recognition element (TRE), can be induced by AP-1 (6). In 
a similar manner to the CREB dimer, AP-1 utilizes an acidic 
activating region to promote RNA polymerase II activity at the 
TATA box, and thereby stimulates gene transcription. In sum, 
cAMP directly activates transcription from CRE-containing 
genes and indirectly from TRE-containing genes via fos. In 
contrast, PIP2 hydrolysis acts indirectly via SRF-mediated fos 
induction to stimulate transcription from genes possessing TRE 
sites. As lithium acutely inhibits both the cAMP and PIP2 
hydrolysis pathways it will be important to consider the link 
between second messengers and gene transcription as a 
mechanism by which chronic lithium regulates gene expression. 
Acute lithium effects on the cAMP system 
The most consistently reproduced finding in lithium 
research is that lithium acutely inhibits neurotransmitter 
(hormone)-, forskolin-, and guanine nucleotide-stimulated 
adenylate cyclase activity in both peripheral tissues and brain 
. 
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(8-10). Interestingly, the persistence of this short term effect is 
clinically manifested in the most common side effect of lithium 
therapy, nephrogenic diabetes insipidus. In the collecting duct 
of the kidney, antidiuretic hormone (ADH) binds to receptors 
and stimulates an increased permeability to water and thereby 
decreases urine volume. Transmembrane signalling of ADH 
occurs via the stimulation of adenylate cyclase, increasing the 
production of cAMP. Lithium inhibits ADH stimulated cAMP 
production and thereby blocks ADH induced water resorption, 
with the net effect of creating a diuresis (11). Another side 
effect of lithium therapy, hypothyroidism, is caused by a 
similar mechanism. Lithium blocks thyroid stimulating 
hormone (TSH) induced cAMP production in the thyroid and 
thereby attenuates TSH-stimulated thyroxine synthesis and 
release (12). In addition to these clinically important side 
effects, lithium inhibits adenylate cyclase in a variety of other 
peripheral tissues including prostaglandin Ei-sensitive 
adenylate cyclase in human platelets, beta-adrenergic-sensitive 
cyclase in human lymphocytes, and epinephrine-sensitive 
cyclase in skeletal muscle (9, 13). 
Some of the earliest evidence for lithium's acute 
inhibition of adenylate cyclase activity in rat brain was derived 
by in vitro studies. Forn and Valdecasas demonstrated that the 
addition of exogenous lithium (2 mM) to both cortical slices and 
homogenates significantly decreased the ability of 
norepinephrine (NE) to stimulate adenylate cyclase activity 
(14). The same effect was observed when NaF was used to 
stimulate the enzyme. These studies pre-date the discovery of 
G-proteins and the insight that NaF directly activates Gsa; 
however, in retrospect, the authors clearly demonstrated that 
lithium acutely blocks adenylate cyclase activation at the post¬ 
receptor level. The major criticism of these studies is the lack 
of data at more clinically relevant lithium concentrations (ie. 
.75 mM - 1.5 mM). Nevertheless, these early studies provided 
much of the focus on adenylate cyclase as a target for lithium 
action. 
. 
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Later studies corroborated that lithium inhibits adenylate 
cyclase activation in brain. Ebstein et. al. (1980) demonstrated 
that lithium inhibits NE-induced cAMP accumulation in 
synaptosomes and slices from rat cortex (9). In addition, these 
studies demonstrated that other ionic elements, rhubidium and 
cesium, do not exert this effect. 
More recent studies have approached the question of 
lithium action with a much better understanding of signal 
transduction and a better arsenal of pharmacologic agents 
which act directly on G-proteins. Newman and Belmaker 
demonstrated that Mn++, forskolin, and GppNHp activation of 
adenylate cyclase were significantly inhibited by lithium in 
cortical membranes (8). Interestingly, inhibition of the activity 
stimulated by forskolin and GppNHp was competitively 
reversible in the presence of Mg++. The emerging picture from 
these investigations is that lithium acts at the post-receptor 
level of G-proteins and/or adenylate cyclase and that this 
action is reversible in the presence of Mg++- 
Lithium’s attenuation of receptor activated adenylate 
cyclase stimulation raises the question of a putative site and 
mechanism for lithium's acute actions. Mork and Geisler have 
studied the effects of lithium on the stimulation kinetics of 
isolated adenylate cyclase from solubilized rat brain (15). 
These studies confirm that lithium inhibits calcium- and 
forskolin- stimulated adenylate cyclase activity. Once again, 
lithium's inhibitory effect was blocked by the presence of 
excess Mg++ (15). These findings raise the possibility that 
lithium displaces Mg++ from its binding site on adenylate 
cyclase where Mg++ is believed to aid in binding ATP for 
conversion to cAMP. 
In more recent attempts to define a post-receptor site of 
lithium action, Avissar et. al. demonstrated that lithium 
attenuates agonist stimulated GTP binding by cholera toxin- 
and pertussis toxin-sensitive G proteins in vitro and in vivo 
(16). This effect persists with chronic lithium treatment 
in vivo. These data are quite remarkable in that agonist 
< 
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stimulated GTP binding is completely abolished in the presence 
of therapeutic concentrations of lithium. These studies suggest 
that lithium acts directly on G-proteins to attenuate the actions 
of receptor agonists. It is possible that lithium acts at a 
nucleotide triphosphate binding site on G-proteins, similar to 
the ATP-binding site on adenylate cyclase, to interfere with G- 
protein function. It is interesting to consider that the cloned 
sequence of adenylate cyclase (type 1) contains a region near 
the amino terminus which is identical to the highly conserved 
region of the guanine nucleotide binding site on G-proteins 
(17) . Therefore lithium may act in a similar manner on both G- 
protein and adenylate cyclase, by displacing Mg+ + , thereby 
preventing protein-nucleotide triphosphate interaction. In sum, 
lithium appears to act at both the level of G-proteins and 
adenylate cyclase to inhibit the synthesis of cAMP in response 
to neurotransmitter stimulation. 
Acute lithium effects on the PIP? system 
A widely held view of lithium action is based on its 
effects on the PIP2 hydrolysis second messenger pathway. 
According to the inositol depletion hypothesis, lithium acutely 
inhibits inositol phosphate phosphatases, thereby preventing 
the recycling of free inositol for de novo PIP2 synthesis (Fig. 3) 
(18) . Upon hydrolysis from PIP2, IP3 can undergo two different 
fates -- further phosphorylation to form IP4, IP5, and IP6 
(whose functions as intracellular messengers are currently 
being investigated) or dephosphorylation to different forms of 
inositol biphosphates and inositol monophosphates. In order to 
regenerate free inositol for novel PIP2 synthesis, it is necessary 
for the inositol monophosphates to undergo dephosphorylation 
by the enzyme inositol monophosphate phosphatase. Lithium 
acutely inhibits this reaction. The question which arises is 
whether this prevents de novo PIP2 synthesis as free inositol is 
available in the extracellular environment. The proponents of 
the inositol depletion hypothesis contend that neural tissue is 
unique because there is minimal transport of free inositol 
' 
across the blood-brain barrier. In the proposed absence of both 
extracellular and intracellular free inositol, neural tissue 
supposedly becomes depleted of the membrane phospholipid 
PIP2 (18). 
Perhaps the best evidence supporting this hypothesis is 
the finding that lithium treatment results in an accumulation of 
the precursor molecule CMP-PA which combines with free 
inositol to form PIP2 (ie. inositol levels supposedly become 
insufficient to utilize normal amounts of CMP-PA in the 
synthesis of novel PIP2) (18). The authors also point to the fact 
that lithium treated tissues have decreased agonist-stimulated 
PIP2 hydrolysis. 
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Figure 3. The inositol depletion hypothesis. Lithium blocks key enzymes 
in the recycling of free inositol from inositol polyphosphates and 
monophosphates. The proponents of this theory contend that lithium 
thereby depletes neuronal membranes of PIP2 needed for 
transmembrane signalling. Figure adapted from Berridge et. al. (18). 
The basic tenet of the inositol depletion hypothesis is that 
chronic lithium therapy is proposed to deplete neuronal 
membranes of PIP2 and thereby interfere with 
neurotransmission. However, most of the available evidence 
strongly contradicts this theory. In fact Godfrey et. al. have 
demonstrated a significant increase in PIP2 levels in rat 
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cerebral cortex after lithium therapy (19). Other studies have 
found that chronic lithium slightly increases or does not affect 
PIP2 levels in rat cortex (20). In the absence of any evidence to 
directly support the hypothesized lithium induced depletion of 
brain PIP2 it is important to search for alternative explanations 
of lithium's actions. It is very possible that other mechanisms 
may involve lithium regulation of PIP2 hydrolysis independent 
of its effects on the inositol monophosphate and polyphosphate 
phosphatases. 
In an analagous manner to lithium's attenuation of cAMP 
production, lithium appears to dampen agonist stimulated PIP2 
hydrolysis. Kendall and Nahorski found that therapeutic levels 
of lithium acutely decrease muscarinic stimulated PIP2 
hydrolysis by approximately 60% in rat cortex (21). This effect 
persists with chronic treatment. Interestingly, when chronically 
treated rats are withdrawn from lithium for 18 hours the 
response to carbachol is significantly increased with respect to 
controls. The molecular basis of this rebound effect is unknown, 
but the data suggest that chronic lithium may upregulate one 
or more components in the PIP2 cycle and that upon lithium 
withdrawal this hypersensitive system is unmasked. Chronic 
lithium inhibition of receptor-coupled inositol phospholipid 
hydrolysis has been corroborated in rat cortex as well as 
hippocampus, and striatum (22). Similar findings of lithium 
acutely inhibiting inositol phosphate formation have been 
reported in mouse cortex (23). In sum, these studies suggest 
that lithium acutely inhibits phosphoinositide hydrolysis and 
that this effect persists with chronic administration. 
The electrophysiological consequences of acute lithium 
inhibition of PIP2 hydrolysis were studied in an elegant set of 
experiments performed by Worley et. al. . This study found 
that lithium blocks a phosphoinositide-mediated cholinergic 
response in hippocampal slices (24). In hippocampus, 
adenosine inhibits depolarization, but this effect can be blocked 
by muscarinic stimulation which is mediated by PIP2 
hydrolysis. Muscarinic stimulation is blocked by therapeutic 
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levels of lithium, presumably secondary to lithium inhibition of 
muscarinic stimulated PIP2 hydrolysis. In the presence of 
lithium, the PKC agonist, TPA, can restore the normal 
muscarinic response. These experiments suggest that lithium 
inhibits muscarinic PIP2 hydrolysis and that this can be 
bypassed by TPA-stimulation of PKC (24). 
In sum, there is substantial evidence to suggest that 
lithium acutely attenuates neurotransmitter-stimulated PIP2 
hydrolysis and that this blockade of the second messenger 
system attenuates the electrophysiological response to the 
neurotransmitter. As previously discussed, lithium acutely 
inhibits agonist stimulated G-protein-GTP binding (16). One 
interesting possibility is that lithium blocks PIP2 hydrolysis by 
attenuating the function of the G-protein (ie. G0 or Gi) which 
couples the receptor to PLC activation. 
Lithium regulation of gene expression -- focus on signal 
transducing proteins 
In consideration of past work on the acute effects of 
lithium in signal transduction, we studied the chronic 
adaptations which occur in response to the lithium induced 
perturbations in neuronal function. As regulation of gene 
expression is a crucial mechanism of cellular adaptation, we 
investigated the effects of chronic lithium on the expression of 
genes involved in signal transduction, specifically those genes 
encoding signal transducing proteins that are acutely affected 
by lithium — adenylate cyclase and G-proteins. The validity of 
our rationale is supported by past studies of the long term 
actions of other types of psychotropic drugs including anti¬ 
depressants, anti-psychotics, morphine, and cocaine. These 
drugs produce chronic adaptations in some of the signal- 
transduction proteins that are regulated by the drugs acutely 
(25-28). Although there has been much interest in interactions 
between lithium and cAMP signal transduction, it is only with 
the recent availability of cDNA clones and monoclonal 
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antibodies for adenylate cyclase that our studies could be 
conducted. 
Our approach to the in vivo study of gene expression 
compares changes at both the mRNA and protein level using 
Northern blotting and Western blotting procedures (see 
Methods). We believe it is essential to demonstrate that a drug 
induced change in mRNA is corroborated by a similar change in 
the encoded protein in order for the effect to have functional 
significance. Furthermore, chronic lithium induced changes in 
gene expression were evaluated in terms of both dose 
dependence and time dependence. Clearly the most clinically 
important changes are those that are dependent upon a 
therapeutic dose and time course. 

METHODS 
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Lithium administration 
Male Sprague-Dawley rats (initial weight, 140-160 g) 
were fed pellets containing 0.24% (wt/wt) lithium carbonate 
(Teklad, Madison, WI) for either 6 days ("short-term lithium") 
or 4 weeks ("therapeutic lithium") according to established 
protocols (29). In some experiments, rats were fed 0.17% 
lithium chloride for 4 weeks ("chronic low-dose lithium"). 
Serum lithium concentrations were measured by the clinical 
laboratories of Yale-New Haven Hospital. The average lithium 
levels from the short-term, therapeutic, and chronic low-dose 
feeding regimens were 0.98 + 0.18, 1.1 ± 0.25, and 0.57 ± 0.14 
mM, respectively. The 6-day treatment period for the short¬ 
term regimen was chosen as the time when serum lithium 
concentrations have reached steady-state (ie., therapeutic) 
levels but when the animal has been exposed to such levels for 
a short time only. The short-term and chronic low-dose lithium 
treatments were utilized to assess the time and dose 
dependence of lithium regulation of adenylate cyclase and G- 
proteins. Control animals were fed the identical diets without 
added lithium. Normal drinking water and hypertonic saline 
(1.5%) were available to all rats ad libitum; this has been 
shown to avoid dehydration in previous investigations (29), 
and there were no signs of dehydration in the current study. 
Rats that received chronic lithium gained weight at a slower 
rate than control rats: from an initial weight of 150 g, control 
and lithium-treated rats weighed, at the end of the 4-week 
treatment period, 250 and 330 g, respectively. However, this 
lithium-induced retarded weight gain per se cannot account 
for the observed regulation of adenylate cyclase and G proteins, 
as chronic treatment of rats with a number of other 
psychotropic drugs (which lead to similar degrees of retarded 
weight gain) do not produce these effects (27, 28, 30 and 
unpublished observations). Lithium administration was 
performed by S.C. . 
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Isolation of RNA and Northern blotting 
At the end of the treatment protocols, cerebral cortex was 
removed rapidly from decapitated animals. Total RNA was 
isolated by guanidinium isothiocyanate extraction followed by 
ultracentrifugation in cesium chloride exactly as described (30). 
Northern blot analysis of adenylate cyclase type 1, adenylate 
cyclase type 2, and G-protein subunit mRNA was carried out 
using 20 fig, 10 fig, and 10 |ig, respectively, of total RNA per 
lane in a 1% agarose gel. Other mRNA types studied include 
PKC subtypes pi, y, PKA subunit Rip, and c-fos, all of which 
required 10 fig of total RNA per lane. The PKA subunit Ca and 
the nuclear protein spl required 20 pg of total RNA per lane. 
RNA in the gels was transferred to nitrocellulose filters, which 
were then hybridized to cDNA probes (labelled with 32P by the 
random primer method; Amersham) for 16 hr at 42°C in the 
presence of 1% (vol/vol) formamide. The cDNA probes used for 
adenylate cyclase and G-proteins are described elsewhere (17, 
31, and unpublished observations). The probes for adenylate 
cyclase type 1 and type 2 each recognized single bands of 
approximately 11.5 and 4.1 kilobases (kb), respectively, as 
found in previous studies (17). The probes for G-protein 
subunits also recognized specific bands as reported previously 
(Giod, 3.5 kb; Gia2, 2.4 kb; Gia3, 3.5 kb; Gsa, 1.9 kb; Goa 4.5 and 
4.1 kb; and Gp, 3.0 kb) (30, 31). The probes for PKC subtypes (31 
and y (kindly provided by John Knopf, Genetics Institute) each 
recognized a 3.5 kb band as previously reported (32). The 
probes for PKA subunits Ca and RI(3 (kindly provided by 
Stanley McKnight, University of Washington, Seattle) 
recognized 2.4 kb and 2.8 kb bands respectively as previously 
reported (33, 34). The probes for c-fos (kindly provided by 
Tom Curran, Roche Institute, New Jersey) and spl (kindly 
provided by Robert Tjian, University of California, Berkeley) 
recognized 2.2 kb and 8.2 kb bands respectively as previously 
reported (35,36). All Northern blots were subsequently 
reprobed with a random-prime 32P-labelled cDNA probe for 
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cyclophilin (kindly provided by J.G. Sutcliffe, Research Institute 
of Scripps Clinic) (37). Resulting blots were dried and 
autoradiographed. Levels of adenylate cyclase and G-protein 
mRNA were quantified by computerized laser densitometry 
(Pharmacia) of autoradiograms or by Betagen (Waltham, MA) 
Betascope analysis of the original blots and normalized to 
cyclophilin mRNA levels by the same instrument. Isolation of 
RNA, Northern blotting, and autoradiography was performed 
by S.C. . 
Immunoblotting 
For adenylate cyclase immunolabelling, cerebral cortex 
was homogenized (20 mg wet weight per ml) in ice-cold 20 mM 
Tris, pH 7.4/1 mM dithiothreitol/1 mM EGTA containing 50 
kallikrein-inhibitor units of aprotinin (Sigma) and 10 fig of 
leupeptin (Sigma) per ml. Homogenates were centrifuged at 
10,000 x g in a refrigerated microcentrifuge for 10 min and 
pellets were resuspended in 1% SDS. Protein content was 
assayed by the method of Lowry et. al. (38). Aliquots of 
resuspended pellets (containing 150-300 |ig of protein) were 
subjected to SDS/polyacrylamide gel electrophoresis with 5% 
acrylamide/0.13% N,N' -methylenebisacrylamide in the 
resolving gels. Proteins were transferred electrophoretically to 
nitrocellulose filters in the presence of 0.025% SDS, and 
resulting filters were immunolabelled for adenylate cyclase as 
described (27). All blotting buffers contained 150 mM NaCl, 
20 mM sodium phosphate (pH 7.4), 0.05% Tween (Sigma), and 
0.5% (wt/vol) nonfat dry milk. A monoclonal antibody (BBC-2; 
1:5000 dilution) prepared against purified adenylate cyclase 
from bovine cerebral cortex (39) and 125I-labelled goat anti¬ 
mouse immunoglobulin (1000 cpm/|il; New England Nuclear) 
were used in these studies. Resulting blots were dried and 
autoradiographed. These conditions recognized two major 
bands of about 150 and 130 kDa, plus a smear between the 
bands. The following lines of evidence support the view that 
this represented specific labelling of adenylate cyclase: (i) the 
-■ 
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labelling was enriched in membrane fractions compared with 
crude homogenates and was fully solubilized by 10 mM Lubrol 
(Sigma) as described previously for adenylate cyclase (39); (ii) 
the labelling was greatly enriched in fractions of neostriatum 
compared with cortex, as is the case for adenylate cyclase (39, 
40); and (iii) the pattern of labelling resembled that reported 
previously for cerebral cortex (39). 
For G-protein immunolabelling, crude homogenates of 
cerebral cortex were adjusted to contain 1% SDS and their 
protein content was determined. Aliquots (10-50 pg of protein) 
were subjected to SDS/polyacrylamide gel electrophoresis (with 
9% acrylamide/0.24% N,N' -methylenebisacrylamide in the 
resolving gels) and to immunolabelling for G-protein subunits 
exactly as described (27,30). Rabbit polyclonal antisera, either 
purchased from New England Nuclear (Gioc 1/2) or kindly 
provided by John Northrup of Yale University (Gp), and 
125I-labelled goat anti-rabbit IgG (300 cpm/pl; New England 
Nuclear) were used in these studies. Levels of G-protein 
immunoreactivity were quantified by densitometry. These 
conditions specifically label G-protein subunits (Giai/2, 
40-41kDa; Gp, 35-36 kDa) and result in linear levels of 
immunoreactivity over a 5-fold range of tissue concentration 
(27,30). Preparation of homogenates and immunoblotting was 
performed by Rose Terwilliger, E.J.N. and S.C. . 
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Lithium regulation of adenylate cvclase 
In initial experiments, lithium regulation of adenylate 
cyclase expression was studied by Northern blotting. Rats were 
treated chronically with lithium under therapeutically relevant 
conditions -- for 4 weeks with final serum levels of 
approximately 1 mM. Such lithium treatment increased mRNA 
levels for both type 1 and type 2 adenylate cyclase by 50-60% 
in cerebral cortex (fig. 4A). 
a • 
AC 1 AC 2 
- + - + - + - + 
B 
150kD—► 
130kD—► 
Figure 4. Autoradiograms illustrating chronic lithium regulation of 
adenylate cyclase expression in rat cerebral cortex. Rats were treated 
chronically with lithium, under therapeutic conditions, as described in 
Methods. Total RNA or membrane fractions, isolated from cerebral 
cortex of control (-) and drug-treated (+) animals, were then subjected 
to Northern blotting (A) or immunoblotting (B) (see Methods). The 
results demonstrate that chronic lithium increases levels of adenylate 
cyclase mRNA and protein. Levels of mRNA for type 1 (AC1) and type 2 
(AC2) adenylate cyclase were, respectively: 159 +. 4%* and 150 + 6%* of 
control +_ s.e.m. (N=6). Levels of adenylate cyclase immunoreactivity 
were difficult to quantify due to the low levels of the enzyme present in 
control cortex; however, the effect shown in the figure was consistent 
among 6 control and 6 treated animals. *P < 0.05 by x2 test. 
In contrast, treatment of rats with lithium for 6 days (with 
final lithium levels of approximately 1 mM) or for 4 weeks but 
at a lower dose (with final lithium levels of approximately 0.5 
mM) failed to alter mRNA levels of either form of adenylate 
. 
. 
. 
cyclase, although there was a tendency for the short-term 
treatment to increase expression of the type 1 enzyme (Fig. 5). 
To determine whether lithium regulation of adenylate 
cyclase mRNA was associated with equivalent regulation of 
enzyme protein, levels of adenylate cyclase immunoreactivity 
were studied by immunoblotting. Chronic treatment of rats 
with lithium under therapeutic conditions produced a dramatic 
induction of adenylate cyclase immunoreactivity (Fig 4B). The 
150 kDa band has been identified in previous studies as a 
calmodulin-insensitive form of adenylate cyclase and most 
likely represents the type 2 enzyme. The 130 kDa band could 
represent the type 1 form of the enzyme, which has been 
reported to migrate between 115 and 135 kDa (39,41,42). 
LITHIUM REGULATION OF 
ADENYLATE CYCLASE mRNA EXPRESSION 
Adenylate 
cyclase 
(type 1) 
Adenylate 
cyclase 
(type 2) 
therapeutic 
short-term 
chronic low-dose 
Figure 5. Time- and dose-dependence of lithium regulation of adenylate 
cyclase mRNA. Rats were treated with lithium under three conditions: 
1) therapeutic: four weeks with final lithium levels of -1 mM; 2) short¬ 
term: six days with final lithium levels of —1.0 mM; or 3) chronic low- 
dose: four weeks at a lower dose with final lithium levels of -0.5 mM (see 
Methods). Total RNA, isolated from cerebral cortex of control and drug- 
treated animals, was then subjected to Northern blotting for type 1 and 
type 2 adenylate cyclase as described in Methods. Data are expressed as 
mean +_ s.e.m. and represent the results obtained from 6-12 control and 
lithium-treated rats. *P < 0.05 by x2 test. 
' 
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Lithium regulation of G-proteins 
Next we studied lithium regulation of G-protein 
expression in cerebral cortex. Administration of lithium under 
therapeutic conditions (i.e., 4 weeks at approximately 1 mM) 
decreased mRNA levels of Giai and Gm2 by approximately 20% 
(Fig. 6A). In contrast, such lithium treatment did not affect 
mRNA levels of the other G-protein subunits studied, which 
included Gsa, G0a, and Gp (Fig. 6A). 
Gial Gia2 
°o • * "sa--^P1 
. + .+ - + -+ - + - + 
-+-+ -+- + 
Figure 6. Autoradiograms illustrating chronic lithium regulation of G- 
protein expression in rat cerebral cortex. Rats were treated chronically 
with lithium, under therapeutic conditions, as described in Methods. 
Total RNA or crude homogenates, isolated from cerebral cortex of 
control (-) and drug-treated (+) animals, were then subjected to 
Northern blotting (A) or immunoblotting (B) (see Methods). The results 
demonstrate that chronic lithium decreases levels of Giai/2 mRNA and 
protein, with no effect seen on other G-protein subunits. Levels of G- 
protein mRNA were normalized to levels of cyclophilin mRNA (Cyc), 
which were not altered by chronic lithium. Levels of G-protein mRNA 
were: Giai, 76 ± 5% (12)*; Gia2, 82 ± 2% (5)*; Goa, 108 ± 9% (6); Gsa, 103 ± 
5% (6); Gp, 103 +_ 9% (6) of control +_ s.e.m. (N). Levels of G-protein 
immunoreactivity were: Giot 1 /2» 83 ±_ 3% (10)*; Gp, 102 ±_ 7% (5) of 
control. Lithium regulation of G-protein mRNA and immunoreactivity 
illustrated in the figure was replicated in two separate experiments. 
*P < 0.05 by j} test. 
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The effect of lithium on Gia3 could not be assessed due to the 
very low resting levels of this G-protein subunit in cerebral 
cortex. Lithium down-regulation of Gia mRNA was only found 
under therapeutic conditions; no effects were seen in response 
to short-term or chronic low-dose treatment (Fig. 7). 
To investigate whether chronic lithium-induced decreases 
in Gia 1/2 mRNA were associated with equivalent changes at the 
protein level, lithium regulation of Gia immunoreactivity was 
investigated. It was found that chronic (therapeutic) lithium 
administration decreased levels of Giai/2 immunoreactivity by 
nearly 20% but had no effect on levels of Gp immunoreactivity 
in cerebral cortex (Fig. 6B). 
LITHIUM REGULATION OF 
G-PROTEIN mRNA EXPRESSION 
Figure 7. Time- and dose-dependence of lithium regulation of Gia 
mRNA. Rats were treated with lithium under three conditions, 
therapeutic, short-term, or chronic low-dose, as described in the legend 
to Figure 5. Total RNA, isolated from cerebral cortex of control and drug- 
treated animals, was then subjected to Northern blotting for Giai and 
Gia2 (see Methods). Data are expressed as mean +_ s.e.m. and represent 
the results obtained from 6-12 control and lithium-treated rats. *P < 0.05 
by x2 test. 
' 
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Lithium does not regulate PKA or PKC 
In order to study possible lithium regulation of other 
signal transducing proteins we conducted Northern blotting 
studies for the PKA catalytic subunit Coe and the regulatory 
subunit Rip. It was found that chronic lithium did not 
significantly affect cortical mRNA levels of either of these PKA 
subunits (Fig. 8A). Similar studies were conducted on PKC 
subtypes pi and y. There was no evidence of lithium regulation 
of these relatively abundant PKC isozymes at the mRNA level 
(Fig. 8B). 
A. 
Ca rip „ . 
- + - + 
PKC pi PKC y 
• •* 
•» * 
- + - + 
Figure 8. Autoradiograms illustrating that chronic lithium does not 
regulate PKA (A) or PKC (B) expression in rat cerebral cortex. Rats were 
treated chronically with lithium, under therapeutic conditions, as 
described in Methods. Total RNA isolated from cerebral cortex of control 
(-) and drug-treated (+) animals were then subjected to Northern 
blotting (see Methods). A. The results demonstrate that chronic lithium 
does not significantly affect PKA subunits Ca and Rip mRNA levels in 
cortex (94 + 4% (6) and 105 +. 3% (6) respectively). B. Chronic lithium 
did not significantly alter PKC subtypes pi and y mRNA levels in cortex 
(107 + 6% (6) and 95 + 7% (6) respectively). 

2 4 
Lithium does not regulate nuclear proteins c-fos or spl 
Our final studies investigated a potential mechanism for 
lithium regulation of adenylate cyclase and G-protein gene 
expression — specifically, possible chronic lithium regulation 
of the transcriptionally active nuclear proteins c-fos and spl. 
Chronic lithium did not significantly alter the cortical mRNA 
levels of either of these transcriptional regulatory proteins 
(Fig. 9). 
c-fos 
- + 
Figure 9. Autoradiograms illustrating that chronic lithium does not 
regulate c-fos or spl expression in rat cerebral cortex. Rats were treated 
chronically with lithium, under therapeutic conditions, as described in 
Methods. Total RNA isolated from cerebral cortex of control (-) and 
drug-treated (+) animals were then subjected to Northern blotting (see 
Methods). The results demonstrate that chronic lithium does not 
significantly affect c-fos or spl mRNA levels in cortex (96 +. 5% (6) and 
107 + 8% (6) respectively). 

25 
DISCUSSION 
Internal controls on quantitative Northern blotting 
As Northern blotting is a complex procedure with many 
opportunities for error including RNA degradation, incomplete 
transfer of RNA, and non-uniform interactions between the 
RNA and the 32P-DNA probe, we first demonstrated that our 
techniques were quantitatively accurate. Successive lanes were 
loaded with 10 ug, 9 ug, 8 ug etc. of RNA and the gel 
underwent electrophoresis and Northern blotting as described 
in Methods. Quantitative analysis revealed a linear decrease in 
radioactive signal (as measured by betascope) across lanes 
corresponding to the decrease in total RNA. These experiments 
indicated that we could reliably compare adjacent lanes to 
quantify drug induced changes in the radioactive signal for the 
probed mRNA. 
Lithium regulation of adenylate cyclase and Gw? 
The results demonstrate that chronic lithium treatment 
increases levels of adenylate cyclase mRNA and protein in rat 
cerebral cortex. Both the calmodulin-sensitive (type 1) and 
calmodulin-insensitive (type 2) forms of adenylate cyclase 
were regulated by chronic lithium administration. These 
findings demonstrate that adenylate cyclase expression, like 
that of other signal transduction proteins, can be regulated in 
the nervous system. Moreover, the results indicate that lithium 
regulation of adenylate cyclase expression may contribute to its 
clinical efficacy, which also requires chronic exposure to 
therapeutic concentrations. 
Previous reports have focused on inhibition of adenylate 
cyclase by acute and chronic lithium. Acute lithium is thought 
to inhibit adenylate cyclase activity at least in part through a 
direct action on the catalytic unit of the enzyme. As previously 
discussed, lithium may compete for Mg++ binding sites on the 
enzyme, which are required for its catalytic activity (15). 
Studies on chronic lithium have reported decreased levels of 
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neurotransmitter-, guanine nucleotide-, and forskolin- 
stimulated adenylate cyclase activity in membranes or slices of 
cerebral cortex (8,9). These inhibitory effects appear to 
represent persistence of the acute inhibitory actions of lithium 
on adenylate cyclase. However, it was also noted in these 
studies that chronic lithium increased basal levels of cAMP 
production by approximately 2-fold in both cerebral cortical 
membranes and slices of cerebral cortex (8,9), and we have 
corroborated these observations by demonstrating that, under 
our treatment conditions, chronic lithium increases basal levels 
of adenylate cyclase activity in cerebral cortical membranes 
(unpublished observations). These observations are consistent 
with the increased levels of adenylate cyclase mRNA and 
protein reported here and indicate that increased basal levels 
of cAMP production and of adenylate cyclase catalytic activity 
could be due to an increase in enzyme expression. In this 
context, up-regulation of adenylate cyclase expression by 
chronic lithium can be viewed as a compensatory, homeostatic 
response to persistent acute inhibition of the enzyme. The 
increases observed in adenylate cyclase expression and basal 
activity appear to predominate over the persistent acute 
inhibition of the enzyme in the chronic lithium-treated state: 
Masana et. al. recently found that chronic lithium produces a 
>2-fold increase in basal extracellular levels of cAMP in 
cerebral cortex as measured by in vivo microdialysis (43). 
These microdialysis studies demonstrate the functional 
physiologic correlate of the lithium induced increase in 
adenylate cyclase expression that we have described. 
Previously, lithium has also been shown to interfere with 
G-protein function acutely (16). Lithium inhibition of GTP 
binding may be associated with an attenuation in the ability of 
neurotransmitters to regulate adenylate cyclase activity. In the 
present study, we have demonstrated that chronic lithium 
decreases Gia expression in cerebral cortex, with no effect 
observed on other G-protein subunits. This decreased 
expression of Gia represents an additional action of lithium on 
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G-proteins which may contribute to its therapeutic efficacy as 
this effect was observed in response to chronic lithium only. 
The observed decrease in levels of Gia, without a change in Gsa 
or Gp, would be expected to decrease the ability of inhibitory 
neurotransmitters to regulate adenylate cyclase activity. This 
action, along with increased adenylate cyclase expression, 
would produce a concerted, and possibly synergistic, up- 
regulation of the adenylate cyclase system in the chronic 
lithium-treated state. In sum, chronic lithium treatment 
appears to have two separate, but related effects -- (i) the 
persistence of an acute inhibition of agonist stimulated cAMP 
production, and (ii) a compensatory increase in basal 
(ie.unstimulated) adenylate cyclase activity. We propose that 
the molecular basis of this second effect is the chronic lithium 
induced change in adenylate cyclase and Gia expression 
described herein. 
Although the effect of chronic lithium on Gia 
expression was relatively small (about 20%), a reduction of this 
magnitude would be expected to exert significant functional 
consequences. It has been shown that inhibition of Gia/G0a by 
10-15% (by pertussis toxin administration) decreases by 40- 
50% the ability of neurotransmitters to produce their 
electrophysiological effects on specific neuronal cell types, 
whereas inhibition of the G-proteins by 40-50% leads to an 
almost complete blockade of the electrophysiological responses 
(45). 
Recent studies on chronic lithium regulation of G-proteins 
have confirmed our findings -- specifically, that chronic lithium 
decreases Giai and Gja2 mRNA in cortex (44). However, in 
contrast to our studies, this report cited a 25% decrease in Gsa 
following chronic lithium (44). It is important to note that this 
study did not provide any data on corresponding changes in 
protein levels, nor did it provide evidence of any G-proteins 
which are not regulated by lithium. It is possible that the 
discrepancy in Gsa findings can be attributed to the use of 
different lithium protocols or different species of rat -- our 
, 
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studies were conducted on Sprague-Dawley rats whereas the 
other studies were conducted on Wistar rats. Finally, it is also 
possible that the discrepancy in Gsa findings is due to 
experimental variation or error. 
Our discussion has focused on lithium regulation of 
"upstream" components — G-proteins and adenylate cyclase — 
in the cAMP cascade. However, it is equally important to 
consider the final common effector in this system, PKA. Recent 
cloning experiments have discovered two distinct catalytic 
subunits, Coe (expressed in periphery and brain) and C(3 
(preferentially expressed in brain), and 4 distinct regulatory 
subunits RIa, Rip, Rlla, and RII(3 (46). Recent studies on lithium 
regulation of PKA activity in cortex reveal that there is no 
change in enzyme activity after chronic treatment (47). This 
would suggest that either there is no change in the level of 
catalytic subunit, or that any change in the catalytic subunit is 
compensated by similar changes in the regulatory subunit. In 
an elegant set of experiments to study co-regulation of catalytic 
and regulatory PKA subunits, McKnight et. al. transfected 3T3 
fibroblasts with a Ca expression vector containing an inducible 
metallothionein promoter. Upon Zn++ administration, Ca mRNA 
and protein rapidly rose to greater than five times basal levels 
(46). Interestingly, there was a significant compensatory 
increase in RI protein with no change in RII (46). It appears 
that there is a pre-programmed mechanism to sequester 
increased Ca expression with increased RI expression (46). This 
homeostasis at the level of gene expression may prevent cells 
from producing excess catalytic subunit, which would be 
constitutively active in the relative absence of regulatory 
subunits (46). It is unclear whether these factors have 
relevance to in vivo cortex conditions. 
In order to study possible chronic lithium regulation of 
PKA we performed Northern blotting studies using cDNA 
probes for several PKA subunits. Our preliminary data suggest 
that neither Ca nor RI{3 mRNA levels are regulated by chronic 
lithium. Studies on the other subunits were difficult due to 
■ 
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either low mRNA levels or high levels of non-specific 32P-DNA 
binding (ie. background). In the absence of positive data at the 
mRNA level we were dissuaded from attempting 
immunoblotting studies on chronic lithium regulation of PKA. 
Possible mechanisms of lithium regulation of gene transcription 
Our findings of chronic lithium regulation of adenylate 
cyclase and Gia expression raise the question of a possible 
molecular mechanism for lithium control of gene transcription. 
Specifically, how might lithium interact with the 
5'-transcriptional control region of these genes. In 
consideration of lithium’s well documented effects on inhibiting 
cAMP production and PIP2 hydrolysis it seems highly plausible 
that lithium affects PKA or PKC regulated gene transcription. 
Under this hypothesis, lithium would decrease cAMP levels, 
and thereby decrease PKA phosphorylation of CREB. This 
change in CREB phosphorylation might directly regulate 
transcription of genes with cAMP regulatory elements. We 
have conducted several computer based searches for cAMP 
regulatory elements in the 5'-non-coding regions of adenylate 
cyclase type 1 (the sequence for type 2 remains unpublished), 
G ia 1 and Gia2 which have confirmed the absence of such 
sequences (17,31). However these searches were confined to 
small regions upstream of the start site as these published gene 
sequences did not extend very far into the 5'-non-coding 
region (17,31). 
Another interesting possibility is that lithium, by 
inhibiting second messenger formation, regulates the 
expression of a secondary transcriptionally active protein and 
that this protein regulates adenylate cyclase, Giai and Gia2 
transcription. Interestingly, all three genes contain multiple 
"GC" boxes in the 5'-non-coding region -- the recognition 
element for the transcriptional regulatory protein spl 
(17,31,48). Accordingly we searched the 5'-non-coding region 
of spl for TRE and CRE sites. Surprisingly we found an estrogen 
hormone regulatory element whose dyad half-site is almost 
- 
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identical to the TRE and CRE: The ERE half-site (underlined) is 
followed by 5'-CA-3' to form 5'-TGACCTCA-3' . This sequence is 
strikingly similar to both the CRE (5'-TGACGTCA-3') and the 
TRE (5'-TGACTCA-3'). Since both CREB and API exhibit 
promiscuity in DNA binding (ie. both proteins are known to 
bind sequences similar to their recognition elements), it is 
plausible that spl is regulated by CREB or API action at this 
site. In order to test our hypothesis that lithium controls spl 
expression (possibly via alterations in CREB or API activity), 
we performed Northern blotting studies on chronic lithium 
treated rat cortex. Unfortunately, spl mRNA is exceedingly rare 
(like many other transcriptionally active nuclear proteins) and 
it was therefore difficult to measure its presence by the 
forestated techniques despite: (i) using excess amounts of total 
RNA (up to 75 ug per lane) , (ii) doubling the specific activity of 
the radiolabelled probe by random labelling with 32P-dATP 
and 32P-dGTP, and (iii) exposing the autoradiogram for up to 14 
days. With these modifications we produced preliminary 
results which suggest that spl is not regulated by lithium. 
Despite these technical difficulties we continued to study 
estrogen regulation of spl. We believe these studies may 
provide the first demonstration of a steroid hormone directly 
regulating a major transcriptional protein. In sum, the 
mechanism by which lithium regulates gene expression of 
specific genes has been elusive and remains to be defined. 
As we have discussed to this point, lithium regulation of 
adenylate cyclase and Gia mRNA and protein is consistent with 
regulation at the level of gene expression, although alternative 
mechanisms, such as regulation of mRNA stability or 
translation, cannot be ruled out. As adenylate cyclase and 
G-proteins are regulated by lithium acutely, it will be 
important to determine whether other acute targets of lithium 
(for example, components of the phosphatidylinositol system) 
are also regulated by chronic lithium treatment. Our results 
suggest that PKC subtypes (31, 8 (unpublished observation), and 
y are not regulated by chronic lithium. These findings are 
■ 
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supported by recent studies which have revealed that chronic 
lithium does not affect PKC activity in cortex (47). In addition, 
studies conducted elsewhere have determined that lithium 
does not affect the levels of IP3-receptor (49). Future studies 
should address the intriguing possibility of lithium regulation 
of PLC. Such studies are particularly interesting in light of the 
finding that chronic lithium followed by 18 hours of 
withdrawal induces an increase in muscarinic stimulated PIP2 
hydrolysis (21). One possibility is that in response to lithium's 
acute inhibition of PIP2 hydrolysis, there is a compensatory 
increase in PLC or the G-protein which couples the receptor to 
PLC. 
The results of the present study indicate that some of the 
chronic effects of lithium on brain function may be mediated 
by alterations in adenylate cyclase and G-protein expression. 
This view is underscored by the fact that these changes were 
fully dependent on a therapeutic dose and time-course. Neither 
short term lithium or chronic low dose lithium induced these 
changes in adenylate cyclase and Gja. Through the study of 
chronic lithium regulation of signal-transducing proteins a 
more complete understanding will emerge concerning the 
mechanisms by which lithium produces its clinical antimanic 
and antidepressant actions. This understanding should help to 
elucidate the molecular basis of manic-depressive disorder. 
■ 
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